Mangoceuticals Inc(MGRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.17 | Insider Own | 11.93% | Shs Outstand | 18.0M | Perf Week | -8.28% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 17.0M | Perf Month | -4.82% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 5.62% | Short Float | 2.58% | Perf Quarter | -2.04% |
| Income | -0.02B | P/S | 25.84 | EPS this Y | - | Inst Trans | 10.97% | Short Ratio | 0.03 | Perf Half Y | -2.52% |
| Sales | 0.00B | P/B | 0.55 | EPS next 5Y | - | ROA | -85.72% | Short Interest | 0.44M | Perf YTD | -48.19% |
| Book/sh | 0.7 | P/C | 35.95 | EPS past 3/5Y | -7.77% -244.95% | ROE | -94.42% | 52W High | -86.06% ($2.75) | Perf Year | -82.57% |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | 270.88% - | ROIC | -118.21% | 52W Low | 136.67% ($0.16) | Perf 3Y | -95.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 63.25% | Gross Margin | -384.9% | Volatility(W/M) | 9.68% 11.05% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 26.12 | Sales Y/Y TTM | -38.91% | Oper. Margin | -4272.95% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.18 | EPS Q/Q | 82.71% | Profit Margin | -5071.14% | RSI (14) | 42.81 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.18 | Sales Q/Q | -59.1% | SMA20 | -12.65% ($0.44) | Beta | 1.98 | Target Price | - |
| Payout | - | Debt/Eq | 0.03 | Earnings | - | SMA50 | -13.34% ($0.44) | Rel Volume | 0.04 | Prev Close | $0.42 |
| Employees | 3 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | - | SMA200 | -13.36% ($0.44) | Avg Volume(3M) | 12.65M | Price | $0.38 |
| IPO | 2023/3/21 | Option/Short | No/Yes | Trades | 673 | Volume | 454,987 | Change | -9.15% |
🥭 This is an early-stage small-cap D2C healthcare company headquartered in Dallas, Texas, specializing in men's wellness telehealth. Under the MangoRx brand, it offers a range of compounded and prescription products for men's health—including erectile dysfunction (ED), hair loss, testosterone replacement, and weight management—through online consultations.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 4% of its average volume.
MGRX has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,584. Peers typically go for $85.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -95.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #37 of 42 in the industry
Based on market cap of $8M.
BFRG#36 Bullfrog AI Holdings Inc $11M PER - MGRX#37 Mangoceuticals Inc $8M PER - 
HCTI#38 Healthcare Triangle Inc $6M PER - 
ACON#38 Aclarion Inc $6M PER - 
ZCMD#40 Zhongchao Inc $6M PER - 
FAQ
What kind of company is MGRX?
MGRX belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of MGRX?
The market cap of MGRX is approximately $8M, ranking 5,522 within its sector.
What is the 52-week high and low for MGRX?
MGRX has recorded a 52-week high of $2.75 and a low of $0.16.
